Patent ID: 8071607

Claim:
A method of treating a subject for diabetes mellitus type II or obesity, comprising: administering to the subject a therapeutically effective amount of a pharmaceutical composition prepared from a compound of the general formula (I) wherein R 1 is substituted aryl having 6 to 10 carbon atoms or optionally substituted heteroaryl having 5 to 10 ring atoms, wherein the substituents are one or more of R 4 , wherein R 4 is independently halogen; CN; COOR 5 ; OR 5 ; C(O)N(R 5 R 5a ); S(O) 2 N(R 5 R 5a ); S(O)N(R 5 R 5a ); S(O) 2 R 5 ; N(R 5 )S(O) 2 N(R 5 R 5a ); SR 5 ; N(R 5 R 5a ); OC(O)R 5 ; N(R 5 )C(O)R 5a ; N(R 5 )S(O) 2 R 5a ; N(R 5 )S(O)R 5a ; N(R 5 )C(O)N(R 5a R 5b ); N(R 5 )C(O)OR 5a ; OC(O)N(R 5 R 5a ); oxo (â•O), where the ring is at least partially saturated; C(O)R 5 ; T 1 ; or C 1-6 alkyl, wherein C 1-6 alkyl is optionally substituted with one or more R 6 ; R 5 , R 5a and R 5b are independently selected from the group consisting of H; T 1 ; and C 1-6 alkyl, wherein C 1 - 6 alkyl is optionally substituted with one or more R 7 ; R 6 , R 7 are independently selected from the group consisting of halogen; CN; COOR 8 ; OR 8 ; C(O)R 8 ; C(O)N(R 8 R 8a ); S(O) 2 N(R 8 R 8a ); S(O)N(R 8 R 8a ); S(O) 2 R 8 ; N(R 8 )S(O) 2 N(R 8a R 8b ); SR 8 ; N(R 8 R 8a ); OC(O)R 8 ; N(R 8 )C(O)R 8a ; N(R 8 )S(O) 2 R 8a ; N(R 8 )S(O)R 8a ; N(R 8 )C(O)N(R 8a R 8b ); N(R 8 )C(O)OR 8a ; OC(O)N(R 8 R 8a ); and T 1 ; R 8 , R 8a , R 8b are independently selected from the group consisting of H; C 1-6 alkyl; and T 1 ; wherein T 1 is C 3-10 cycloalkyl; C 4-10 bicycloalkyl; C 4-10 hetercyclyl; C 4-10 heterobicyclyl; aryl having 6 to 10 carbon C atoms; heteroaryl having 5 to 10 ring atoms, wherein T 1 is optionally substituted with one or more R 9 , wherein R 9 is independently halogen; CN; COOR 10 ; OR 10 ; C(O)N(R 10 R 10a ); S(O) 2 N(R 10 R 10a ); S(O)N(R 10 R 10a ); S(O) 2 R 10 ; N(R 10 )S(O) 2 N(R 10a R 10b ); SR 10 ; N(R 10 R 10a ); OC(O)R 10 ; N(R 10 )C(O)R 10a ; N(R 10 )S(O) 2 R 10a ; N(R 10 )S(O)R 10a ; N(R 10 )C(O)N(R 10a R 10b ); N(R 10 )C(O)OR 10a ; OC(O)N(R 10 R 10a ); oxo (â•O), where the ring is at least partially saturated; C(O)R 10 ; C 1-6 alkyl; phenyl; C 3-7 cycloalkyl; or heterocyclyl, wherein C 1-6 alkyl; phenyl; C 3-7 cycloalkyl; and heterocyclyl are optionally substituted with one or more halogen, which are the same or different; R 10 , R 10a and R 10b are independently selected from the group consisting of H, C 1-6 alkyl, phenyl, C 3-7 cycloalkyl, heteroaryl and heterocyclyl, wherein C 1-6 alkyl, phenyl, C 3-7 cycloalkyl and heterocyclyl are optionally substituted with one or more halogen, which are the same or different; R 2 is hydrogen, C 1-4 alkyl, an acetyl group or a urea; R 3 is hydrogen, a hydroxyl, C 1-4 alkyl; or amino group; and X is a bond; or a pharmaceutically acceptable salt thereof, and optionally a pharmaceutically acceptable carrier.